Angiogenesis News and Research

RSS

Angiogenesis is blood vessel formation. Tumor angiogenesis is the growth of new blood vessels that tumors need to grow. This is caused by the release of chemicals by the tumor.

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.

17 Sep 2013

Elevated miR-200 boosts survival of lung, ovarian, renal, triple-negative breast cancer patients

A family of microRNAs (miR-200) blocks cancer progression and metastasis by stifling a tumor's ability to weave new blood vessels to support itself, researchers at The University of Texas MD Anderson Cancer Center report today in Nature Communications.

12 Sep 2013

Umbilical cord mesenchymal stem cells may have targeting capacity for glioma

Glioblastoma is the most common ma-lignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor microsatellites at distal sites, makes eradication impossible even after extensive microsurgical resection combined with current standard chemoradiation and adjuvant temozolomide.

11 Sep 2013

European Commission approves Stivarga tablets for treatment of patients with mCRC

Bayer HealthCare and Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) announced today that the European Commission has approved Stivarga® (regorafenib) tablets for the treatment of adult patients with metastatic colorectal cancer (mCRC).

30 Aug 2013

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).

29 Aug 2013

Tumor vessel density linked to mRCC treatment response

Changes in tumor vessel density correlate with response and resistance to anti-angiogenic therapy in patients with metastatic renal cell carcinoma, study findings suggest.

28 Aug 2013

FDA grants Priority Review designation to sNDA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted Priority Review designation to the supplemental New Drug Application for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets under evaluation for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

27 Aug 2013

New data analyzing technique via MR imaging identify tumors' response to anti-angiogenesis therapy

A new way of analyzing data acquired in MR imaging appears to be able to identify whether or not tumors are responding to anti-angiogenesis therapy, information that can help physicians determine the most appropriate treatments and discontinue ones that are ineffective.

20 Aug 2013

Advance team of molecules produced by primary tumor is responsible for lung cancer metastasis

Cancer metastasis requires tumor cells to acquire properties that allow them to escape from the primary tumor site, travel to a distant place in the body, and form secondary tumors. But first, an advance team of molecules produced by the primary tumor sets off a series of events that create a network of nurturing blood vessels for arriving primary tumor cells to set up shop.

20 Aug 2013

Report demonstrates clinical use of novel biomarker to assess cancer progression, inflammation

A groundbreaking peer reviewed case report by Dr. Isaac Eliaz, M.D. of Amitabha Medical Clinic, demonstrates for the first time the clinical use of novel biomarker galectin-3 to assess cancer progression and inflammation.

19 Aug 2013

Study reveals cancer in humans linked with high amounts of proteins responsible for cells division

Cancer in humans is frequently associated with unusually high amounts of one or more proteins responsible for controlling the rate at which cells divide. As an example, excessive amounts of the cyclin-dependent kinase CDK6 are often found in types of cancer such as lymphoma.

14 Aug 2013

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

A team of scientists, led by Napoleone Ferrara, MD, has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.

6 Aug 2013

BioLineRx reports positive results from pre-clinical trials with RHB-104 for treatment of thrombocytopenia

BioLineRx, a biopharmaceutical development company, announced today that BL-8040 has been shown in pre-clinical trials to be effective for the treatment of thrombocytopenia, or reduced platelet production.

5 Aug 2013

ASH to award 2013 William Dameshek Prize to Andrew S. Weyrich

The American Society of Hematology will present the 2013 William Dameshek Prize to Andrew S. Weyrich, PhD, of The University of Utah for his seminal research on the cellular and molecular causes of blood clots.

2 Aug 2013

Severe arthritis pain treatments: an interview with Professor Walsh, University of Nottingham and Professor Wood, UCL

Pain is defined by the sufferer’s experience. Pain may be severe because it is intense, frequent or sustained, and because it is distressing. The severity of pain is not simply due to what is going on in the joint, but is also affected by how the body processes the pain signals, and the context in which it is experienced.

31 Jul 2013

Creating, promoting foods containing angiogenesis is the new frontier in dietary health

Creating and promoting foods that contain natural inhibitors of unhealthy angiogenesis - the formation of blood vessels that feed and promote disease, obesity and inflammation - is the "new frontier in dietary health," according to a presentation at the 2013 Institute of Food Technologists Annual Meeting & Food Expo- in Chicago.

18 Jul 2013

Researchers discover new protein that encourages ‘bad’ blood vessel growth

The discovery of a protein that encourages blood vessel growth, and especially 'bad' blood vessels - the kind that characterise diseases as diverse as cancer, age-related macular degeneration and rheumatoid arthritis - has been reported in the journal Nature.

18 Jul 2013

Research shows hydrogen sulfide is a key player in colon cancer metabolism

University of Texas Medical Branch at Galveston researchers have discovered that hydrogen sulfide - the pungent-smelling gas produced by rotten eggs - is a key player in colon cancer metabolism, and a potential target for therapies for the disease.

9 Jul 2013

Bayer, Onyx submit sNDA to FDA, marketing authorization application to EMA for Nexavar tablets

Bayer HealthCare and Onyx Pharmaceuticals today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration and an application for marketing authorization to the European Medicines Agency for the oral multi-kinase inhibitor Nexavar (sorafenib) tablets for the treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer.

1 Jul 2013

Researchers develop new drug delivery systems to treat cancer by blocking signaling receptor

A cardiac hormone signaling receptor abundantly expressed both in inflamed tissues and cancers appears to recruit stem cells that form the blood vessels needed to feed tumor growth, reports a new study by scientists at the University of South Florida Nanomedicine Research Center.

30 Jun 2013